Navigation Links
Verenium Announces Organizational Changes
Date:4/3/2009

CAMBRIDGE, Mass., April 3 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of high-performance specialty enzymes and next-generation cellulosic ethanol, today announced that following the successful commissioning of Verenium's demonstration-scale facility in Jennings, Louisiana, and the recent announcement of a commercial joint venture with BP, Verenium is now consolidating its research and development (R&D) organization, including the pilot and demonstration-scale biofuels operations in Jennings, Louisiana, under Gregory Powers, Ph.D., Executive Vice President, R&D. This new organizational structure provides Verenium with a unique set of integrated R&D assets from the laboratory through a 1.4 million-gallon-per-year demonstration-scale facility for the efficient development, implementation and testing of its biofuels technologies.

As a result of this organizational change, John R. Malloy, Executive Vice President of Biofuels, has left the Company to pursue other opportunities. He will continue to serve as a consultant to the Company.

"I'd like to thank John for his leadership, dedication and significant contributions to Verenium's biofuels development efforts; we wish him all the best and continued success in his future endeavors," said Carlos A. Riva, President and Chief Executive Officer of Verenium.

About Verenium

Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and animal health markets. The Company possesses integrated, end-to-end capabilities and cutting-edge technology in pre-treatment, novel enzyme development, fermentation an
'/>"/>

SOURCE Verenium Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
2. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
3. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
4. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
5. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
6. Verenium Reports Financial Results for the First Quarter 2008
7. Verenium Appoints John F. Dee to Board of Directors
8. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
9. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
10. Verenium Corporation to Announce Third Quarter 2008 Financial Results
11. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Oven Industries Inc. announces a new ... 5R6-900 benchtop controller has many outstanding user-friendly benefits. Contained ... into the wall as a self-contained temperature control system, ... makes the device unique, as well as highly convenient ... can also be used universally, which allows the user ...
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific Shore ... based products across a broad range of product ... retained investor relations firm, BlueWater Advisory Group, to ... to trading process, and to direct the company,s ... Matthew Mills , ...
(Date:5/20/2013)... With bed bugs' presence come problems in various terms. ... to be eliminated, one must make sure that the bed ... so to help bed bug sufferers get that done, it ... bugs without using harmful pesticides. In it, the company ... Bug Bully. , According to My Cleaning Products, contrary to ...
(Date:5/20/2013)... 2013   Flexion Therapeutics , Inc. today announced ... to its management team as chief financial officer. ... management experience with biotechnology and medical device companies. ... financial officer for Novavax (NASDAQ: NVAX ) ... $250 million through a combination of investment funding and ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Pacific Shore Holdings Retains Investor Relations Firm 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2
... Incorporated,(Nasdaq: GPRO ) announced today that the Company ... on Tuesday, September 9,2008 at approximately 2:45 p.m. Eastern ... may be accessed through a link on the investors,section ... be available for 30 days following the event., ...
... during industry-leading event September 10 - 11, ... 2008 ... Plexus Systems, Inc.,provider of Plexus Online on-demand software for the ... 10-11, 2008 at the San Jose McEnery Conference Center, San ...
... The 33rd ESMO Congress,in Stockholm, the premier European ... medical oncologists, as well as a focal point ... The Congress Centre will be the venue for ... discuss critical issues for,European oncology such as cancer ...
Cached Biology Technology:Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference 2Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference 233rd ESMO Congress in Stockholm, 12-16 September 2008 233rd ESMO Congress in Stockholm, 12-16 September 2008 333rd ESMO Congress in Stockholm, 12-16 September 2008 433rd ESMO Congress in Stockholm, 12-16 September 2008 5
(Date:5/20/2013)... - A National Science Foundation (NSF) planning grant will ... (CARD), a joint program of the University of Illinois ... Mass. , "CARD will be devoted to research in ... agricultural products; forestry and paper products; chemical products; textiles; ... professor of food science and human nutrition and the ...
(Date:5/19/2013)... A novel study reports that white men and women ... bunions (hallux valgus) and lesser toe deformities, including hammer ... first to estimate the heritability of foot disorders in ... journal published by Wiley on behalf of the American ... that as many as 60% of older adults have ...
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) explores ... the impact of coffee on autoimmune disease and palliative ... recently has been associated with reduced risk of fibrosis, ... cups of java each month also correlate with lower ... the Mayo Clinic, Rochester, MN, linked coffee consumption with ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Blame your parents for bunion woes 2Coffee consumption associated with reduced risk of autoimmune liver disease 2
... blood clot-dissolving medication that is administered to some patients ... reduce the risk of amputation following severe frostbite, according ... of Surgery, one of the JAMA/Archives journals. , Frostbite ... 25 years, according to background information in the article. ...
... the University of Central Florida is proving promising as ... disease that can cause blindness and affects millions of ... the blood-brain barrier making it an effective non-toxic tool ... with appointments in UCF’s Advanced Materials Processing and Analysis ...
... A major obstacle in the treatment of infections and ... which prevents systemically delivered therapeutic drugs from reaching the ... Infectious Diseases, part of the National Institutes of Health, ... the rabies virus can carry a strip of therapeutic ...
Cached Biology News:Clot-dissolving agent may be beneficial in treatment of severe frostbite 2UCF nanoparticle offers promise for treating glaucoma 2Blood-brain barrier breached by new therapeutic strategy 2
Request Info...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
Anti Human JAM-1, Monoclonal Antibody, Clone M.Ab.F11...
Biology Products: